Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in TRANSCEND NHL 001

Further data from the TRANSCEND NHL 001 study supporting the role of CART therapy in mantle cell lymphoma. However it appears the rate of toxicity is just a little higher than in the DLBCL indication. Is this related to burden of disease and disease distribution ?